drugset
drugset / Trial / NCT02714374

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

NCT02714374 ↗

Phase 1 Terminated 5 enrolled Andrew Lowy Genelux GmbH · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells. Vaccinia virus has been used successfully in the past as smallpox vaccine in millions of people worldwide.

Timeline

Start
2016-03-25
Primary completion
2019-08-06
Completion
2019-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Olvimulogene nanivacirepvec Other / unclassified 1e+09 unknown Intravenous
Subject Olvimulogene nanivacirepvec Other / unclassified 2e+09 unknown Intravenous
Subject Olvimulogene nanivacirepvec Other / unclassified 5e+09 unknown Intravenous

Indications

cancer